MGMT Promoter Methylation as an Epigenetic Biomarker for the Estimation of Chemosensitivity towards the Alkylating Agents Based Chemotherapies

The repair enzyme MGMT is recognized as having a provocative clinical relevance linked with cancerogenesis mechanisms and also with the chemosensitivity to particular oncological treatments including alkylating agents. Therefore, the analytical methods designed for the function of the gene encoding MGMT are actually developed in order to respond to specific needs, regarding diagnosis and predictive or prognostic approaches of treatments.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research